Ryan Savitz - Dec 4, 2025 Form 4 Insider Report for Dianthus Therapeutics, Inc. /DE/ (DNTH)

Role
CFO & CBO
Signature
/s/ Adam Veness, as attorney-in-fact for Ryan Savitz
Stock symbol
DNTH
Transactions as of
Dec 4, 2025
Transactions value $
-$734,800
Form type
4
Date filed
12/5/2025, 08:00 PM
Previous filing
Sep 25, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Savitz Ryan CFO & CBO C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK /s/ Adam Veness, as attorney-in-fact for Ryan Savitz 2025-12-05 0001992324

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNTH Common Stock Options Exercise $169K +20K $8.44 20K Dec 4, 2025 Direct F1
transaction DNTH Common Stock Sale -$904K -20K -100% $45.18 0 Dec 4, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNTH Stock Option (Right to Buy) Options Exercise $0 +20K +30.88% $0.00 84.8K Dec 4, 2025 Common Stock 20K $8.44 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2025.
F2 The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.